Literature DB >> 20683549

Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis.

Gianfranco Ferraccioli1, Luisa Bracci-Laudiero, Stefano Alivernini, Elisa Gremese, Barbara Tolusso, Fabrizio De Benedetti.   

Abstract

Tumor necrosis factor-α (TNF-α) is the major target of the therapeutic approach in rheumatoid arthritis. A key issue in the approach to chronic arthritis is the understanding of the crucial molecules driving the transition from the acute phase to the chronic irreversible phase of the disease. In this review we analyzed five experimental arthritis animal models (antigen-induced arthritis, adjuvant-induced arthritis, streptococcal cell wall arthritis, collagen-induced arthritis and SKG) considered as possible scenarios to facilitate interpretation of the biology of human rheumatoid arthritis. The SKG model is strictly dependent on interleukin (IL)-6. In the other models, IL-1β and IL-6, more than TNF-α, appear to be relevant in driving the transition, which suggests that these should be the targets of an early intervention to stop the course toward the chronic form of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683549      PMCID: PMC2972398          DOI: 10.2119/molmed.2010.00067

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  44 in total

1.  The arthritogenic T cell receptor and its ligand in a model of spontaneous arthritis.

Authors:  S Mangialaio; H Ji; A S Korganow; V Kouskoff; C Benoist; D Mathis
Journal:  Arthritis Rheum       Date:  1999-12

2.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  Severe inflammatory arthritis and lymphadenopathy in the absence of TNF.

Authors:  I K Campbell; K O'Donnell; K E Lawlor; I P Wicks
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

4.  Systemic macrophage activation in locally-induced experimental arthritis.

Authors:  J Simon; R Surber; G Kleinstäuber; P K Petrow; S Henzgen; R W Kinne; R Bräuer
Journal:  J Autoimmun       Date:  2001-09       Impact factor: 7.094

5.  Cytokine expression and synovial pathology in the initiation and spontaneous resolution phases of adjuvant arthritis: interleukin-17 expression is upregulated in early disease.

Authors:  K A Bush; J S Walker; C S Lee; B W Kirkham
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

6.  Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis.

Authors:  Z Szekanecz; M M Halloran; M V Volin; J M Woods; R M Strieter; G Kenneth Haines; S L Kunkel; M D Burdick; A E Koch
Journal:  Arthritis Rheum       Date:  2000-06

7.  Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.

Authors:  S M Hurst; T S Wilkinson; R M McLoughlin; S Jones; S Horiuchi; N Yamamoto; S Rose-John; G M Fuller; N Topley; S A Jones
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

8.  Cytokine mRNA in the joints and draining lymph nodes of rats with adjuvant arthritis and effects of cyclosporin A.

Authors:  L M Ayer; A C Issekutz; C C Waterhouse; A W Stadnyk
Journal:  Inflammation       Date:  2000-10       Impact factor: 4.092

9.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

Authors:  T Jostock; J Müllberg; S Ozbek; R Atreya; G Blinn; N Voltz; M Fischer; M F Neurath; S Rose-John
Journal:  Eur J Biochem       Date:  2001-01

10.  Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis.

Authors:  Mari A Nowell; Anwen S Williams; Sarah A Carty; Jürgen Scheller; Anthony J Hayes; Gareth W Jones; Peter J Richards; Simon Slinn; Matthias Ernst; Brendan J Jenkins; Nicholas Topley; Stefan Rose-John; Simon A Jones
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

View more
  32 in total

1.  Impact of IL-1 signalling on experimental uveitis and arthritis.

Authors:  Stephen R Planck; April Woods; Jenna S Clowers; Martin J Nicklin; James T Rosenbaum; Holly L Rosenzweig
Journal:  Ann Rheum Dis       Date:  2012-01-20       Impact factor: 19.103

2.  Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA).

Authors:  Gianfranco Ferraccioli; Elisa Gremese
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

3.  Paclitaxel suppresses collagen-induced arthritis: a reevaluation.

Authors:  Yi Zhao; Zhi-Fang Chang; Ru Li; Zhan-Guo Li; Xiao-Xia Li; Lin Li
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

4.  Anethole reduces inflammation and joint damage in rats with adjuvant-induced arthritis.

Authors:  Alessandra Mileni Versuti Ritter; Luzmarina Hernandes; Bruno Ambrosio da Rocha; Camila Fernanda Estevão-Silva; Edirlene Sara Wisniewski-Rebecca; Joice Dos Santos Cezar; Silvana Martins Caparroz-Assef; Roberto Kenji Nakamura Cuman; Ciomar Aparecida Bersani-Amado
Journal:  Inflamm Res       Date:  2017-05-25       Impact factor: 4.575

5.  Inhibition of small HA fragment activity and stimulation of A2A adenosine receptor pathway limit apoptosis and reduce cartilage damage in experimental arthritis.

Authors:  Giuseppe M Campo; Antonio Micali; Angela Avenoso; Angela D'Ascola; Michele Scuruchi; Antonina Pisani; Antongiulio Bruschetta; Alberto Calatroni; Domenico Puzzolo; Salvatore Campo
Journal:  Histochem Cell Biol       Date:  2014-12-16       Impact factor: 4.304

6.  Chemically modified N-acylated hyaluronan fragments modulate proinflammatory cytokine production by stimulated human macrophages.

Authors:  Oladunni Babasola; Karen J Rees-Milton; Siziwe Bebe; Jiaxi Wang; Tassos P Anastassiades
Journal:  J Biol Chem       Date:  2014-07-22       Impact factor: 5.157

7.  Protective effect of methyl gallate on murine antigen-induced arthritis by inhibiting inflammatory process and bone erosion.

Authors:  Luana Barbosa Correa; Tatiana Almeida Pádua; Paulo Vinicius Gil Alabarse; Elvira Maria Saraiva; Esdras Barbosa Garcia; Fabio Coelho Amendoeira; Fausto Klabund Ferraris; Sandra Yasuyo Fukada; Elaine Cruz Rosas; Maria G Henriques
Journal:  Inflammopharmacology       Date:  2022-02-02       Impact factor: 4.473

8.  Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model.

Authors:  Li-Wei Chou; John Wang; Pei-Lin Chang; Yueh-Ling Hsieh
Journal:  Arthritis Res Ther       Date:  2011-06-16       Impact factor: 5.156

9.  A dried yeast fermentate prevents and reduces inflammation in two separate experimental immune models.

Authors:  Malkanthi Evans; Stuart Reeves; Larry E Robinson
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-05       Impact factor: 2.629

10.  Endogenous galectin-1 exerts tonic inhibition on experimental arthritis.

Authors:  Asif J Iqbal; Dianne Cooper; Alexander Vugler; Beatrice R Gittens; Adrian Moore; Mauro Perretti
Journal:  J Immunol       Date:  2013-05-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.